tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Roth D et al. A prospective study of hepatitis C virus infection in renal allograft recipients. 1996 Transplantation pmid:8623154
Koprak S et al. Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. 1996 Transplantation pmid:8623162
Ciancio G et al. Current advantage of FK 506 in cadaveric kidney transplantation. 1996 Transplant. Proc. pmid:8623207
Pham SM et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. 1996 Transplant. Proc. pmid:8623208
Satomura K et al. Pharmacokinetics of FK 506 in living-related liver transplantation. 1996 Transplant. Proc. pmid:8623209
Loss M et al. Glucose and lipid metabolism in liver transplant patients under long-term tacrolimus (FK 506) monotherapy. 1996 Transplant. Proc. pmid:8623210
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Kogi M et al. Effects of calyculin A and FK506 on the O2- generation of rat peritoneal macrophages. 1996 Tokai J. Exp. Clin. Med. pmid:9239803
Harrison DM et al. Reduction in hospital stay after liver transplantation. 1996 Transplant. Proc. pmid:8623451
Andrews WS et al. Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation. 1996 Transplant. Proc. pmid:8623452
Ketel BL et al. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation. 1996 Transplant. Proc. pmid:8623453
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
D'Silva M et al. Immunosuppressive effect of RS-61443 on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623467
Pirenne J et al. Bone marrow augmentation of kidney allografts can cause graft-versus-host disease in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623472
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
D'Silva M et al. Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623476
Muraoka K et al. Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. 1996 J. Clin. Invest. pmid:8647935
Brunke M et al. Luciferase assembly after transport into mammalian microsomes involves molecular chaperones and peptidyl-prolyl cis/trans-isomerases. 1996 J. Biol. Chem. pmid:8798557
Zhang Q et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8799169
Spencer DM et al. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. 1996 Curr. Biol. pmid:8805308
Franke EK and Luban J Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. 1996 Virology pmid:8806510
Ichikawa Y et al. Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. 1996 Int. J. Urol. pmid:8776613
Mugiya S et al. Renal blood flow and serotonin metabolism in tacrolimus treated rats. 1996 Int. J. Urol. pmid:8776615
Dmitrewski J et al. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. 1996 J. Hepatol. pmid:8778189
Schwarz A [Drug-induced kidney damage]. 1996 Z Arztl Fortbild (Jena) pmid:8779233
Lu YF et al. FK506, a Ca2+/calmodulin-dependent phosphatase inhibitor, inhibits the induction of long-term potentiation in the rat hippocampus. 1996 Neurosci. Lett. pmid:8907327
Ye Q et al. Persistence of donor cells and incidence of graft-versus-host disease after simultaneous small bowel and bone marrow transplantation. 1996 Transplant. Proc. pmid:8907895
Walgenbach KJ et al. Increased presence of mast cells and interleukin-4 during chronic rejection of rat intestinal allografts. 1996 Transplant. Proc. pmid:8907896
Nüssler NC et al. CD8+ host cells infiltrate the intestinal mucosa after allogeneic small bowel transplantation even in the absence of acute rejection. 1996 Transplant. Proc. pmid:8907898
Wu J et al. Reversal of multidrug resistance by tacrolimus hydrate. 1996 Methods Find Exp Clin Pharmacol pmid:9121220
Perego C et al. Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907908
Alessiani M et al. Combined FK 506 and mycophenolate mofetil immunosuppression prolongs survival after small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907922
Cohen DS et al. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy. 1996 Transplant. Proc. pmid:8907923
Toyama Y et al. Prolonged small bowel graft survival using photochemotherapy and low-dose FK 506. 1996 Transplant. Proc. pmid:8907924
Woodle ES et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplantation pmid:8830821
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Ho S et al. The mechanism of action of cyclosporin A and FK506. 1996 Clin. Immunol. Immunopathol. pmid:8811062
Nishino H et al. 3-Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression. 1996 J. Chem. Neuroanat. pmid:8811425
Sonatore LM et al. The utility of FK506-binding protein as a fusion partner in scintillation proximity assays: application to SH2 domains. 1996 Anal. Biochem. pmid:8811923
Jonas S et al. Conversion to tacrolimus after liver transplantation. 1996 Transpl. Int. pmid:8748407
Cooley HM et al. Resolution of pyoderma gangrenosum using tacolimus (FK-506) 1996 Aust N Z J Med pmid:8744629
Hashino S et al. Antitumor effect in cyclosporine A- or FK506-treated mice after syngeneic bone marrow transplantation. 1996 Leuk. Lymphoma pmid:8726416
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplant. Proc. pmid:8962225
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Kliem V et al. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. 1996 Transplant. Proc. pmid:8962227
Becker G et al. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. 1996 Transplant. Proc. pmid:8962228
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Braun F et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. 1996 Transplant. Proc. pmid:8962231
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Shinozuka N et al. Correlation between simplified immunocompetence assay and clinical graft states in kidney or liver transplant recipients. 1996 Transplant. Proc. pmid:8658649
Nishimura Y et al. Whole organ vascularized thymus allografting effectively modulates cardiac rejection. 1996 Transplant. Proc. pmid:8658660
Tanabe K et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. 1996 Transplant. Proc. pmid:8658670
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Degawa H et al. Blocking of ICAM-1 and LFA-1 in rat liver transplantation. 1996 Transplant. Proc. pmid:8658695
Watanabe K et al. Immunosuppressive effect of bactobolamine in rat liver allotransplantation. 1996 Transplant. Proc. pmid:8658697
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Yuzawa K et al. Topical immunosuppression in skin grafting with FK 506 ointment. 1996 Transplant. Proc. pmid:8658707
Woodle ES et al. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. 1996 Clin Transplant pmid:8884103
Karashima T et al. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. 1996 J. Dermatol. Sci. pmid:8884530
Monfar M and Blenis J Inhibition of p70/p85 S6 kinase activities in T cells by dexamethasone. 1996 Mol. Endocrinol. pmid:8885245
Andoh TF et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. 1996 Kidney Int. pmid:8887267
Shapiro R et al. "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. 1996 Transplantation pmid:8932264
Mysliwiec J et al. The effect of tacrolimus (FK506) and cyclosporin A (CyA) on peripheral serotonergic mechanisms in uremic rats. 1996 Thromb. Res. pmid:8837316
Devlin J and Williams R Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. 1996 Transplantation pmid:8932266
Lamb GD and Stephenson DG Effects of FK506 and rapamycin on excitation-contraction coupling in skeletal muscle fibres of the rat. 1996 J. Physiol. (Lond.) pmid:8842013
Curran CF et al. Acute overdoses of tacrolimus. 1996 Transplantation pmid:8932293
Tanaka K et al. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. 1996 Pharm. Res. pmid:8842048
Bader A et al. Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry. 1996 Naunyn Schmiedebergs Arch. Pharmacol. pmid:8935714
Thompson PA and Mosley CA Tacrolimus-phenytoin interaction. 1996 Ann Pharmacother pmid:8740340
Christophers E Psoriasis: mechanisms and entry points for possible therapeutic interventions. 1996 Australas. J. Dermatol. pmid:8713012
Alak AM and Lizak P Stability of FK506 in blood samples. 1996 Ther Drug Monit pmid:8721287
Büttemeyer R et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. 1996 Plast. Reconstr. Surg. pmid:8532772
Yu C et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. 1996 Bone Marrow Transplant. pmid:8722370
Fealy MJ and Press BH Pinpointing the moment of allograft rejection. 1996 J Hand Surg Am pmid:8724501
Hall MN The TOR signalling pathway and growth control in yeast. 1996 Biochem. Soc. Trans. pmid:8674674
Cox KL and Freese DK Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation. 1996 Clin Invest Med pmid:8889279
Bridges ND et al. Lung transplantation in infancy and early childhood. 1996 J. Heart Lung Transplant. pmid:8889985
Iwasaki K et al. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. 1996 Res. Commun. Mol. Pathol. Pharmacol. pmid:9029671
Bousvaros A et al. Tacrolimus (FK-506) treatment of fulminant colitis in a child. 1996 J. Pediatr. Gastroenterol. Nutr. pmid:8890089
De Rie MA et al. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. 1996 Acta Derm. Venereol. pmid:8891007
Timmerman LA et al. Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression. 1996 Nature pmid:8893011
Inutsuka K et al. Reconstruction of trachea and carina with immediate or cryopreserved allografts in dogs. 1996 Ann. Thorac. Surg. pmid:8893587
Ezeamuzie CI Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. 1996 Int. J. Immunopharmacol. pmid:8894806
Tokunaga Y and Alak AM FK506 (tacrolimus) and its immunoreactive metabolites in whole blood of liver transplant patients and subjects with mild hepatic dysfunction. 1996 Pharm. Res. pmid:8668663
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Dhar DK et al. FK506 maintains cellular calcium homeostasis in ischemia-reperfusion injury of the canine liver. 1996 J. Surg. Res. pmid:8592405
Kay JE Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. 1996 Biochem. J. pmid:8670043
Schmaldienst S and Horl WH Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. 1996 Nephrol. Dial. Transplant. pmid:8672015
Taylor PJ et al. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. 1996 Clin. Chem. pmid:8595724
Hartley AD et al. cAMP inhibits bud growth in a yeast strain compromised for Ca2+ influx into the Golgi. 1996 Mol. Gen. Genet. pmid:8709962
Tokime T et al. Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil. 1996 Neurosci. Lett. pmid:8710192
Dan Y et al. IL-3 augments TCR-mediated responses of type 2 CD4 T cells. 1996 J. Immunol. pmid:8598473
Soubrane O and Houssin D [Liver transplantation. Current aspects]. 1996 Presse Med pmid:8728904
Beretta L et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. 1996 EMBO J. pmid:8599949
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635